Mechanism of action of pre-meal consumption of whey protein on glycemic control in young adults

Mechanism of action of pre-meal consumption of whey protein on glycemic control in young adults

    Mechanism Of Action Of Pre-Meal Consumption Of Whey Protein On Glycemic Control In Young Adults Tina Akhavan, Bohdan L. Luhovyy, Shir...

2MB Sizes 2 Downloads 29 Views

    Mechanism Of Action Of Pre-Meal Consumption Of Whey Protein On Glycemic Control In Young Adults Tina Akhavan, Bohdan L. Luhovyy, Shirin Panahi, Ruslan Kubant, Peter H. Brown, G. Harvey Anderson PII: DOI: Reference:

S0955-2863(13)00183-6 doi: 10.1016/j.jnutbio.2013.08.012 JNB 7093

To appear in:

The Journal of Nutritional Biochemistry

Received date: Revised date: Accepted date:

12 February 2013 27 August 2013 30 August 2013

Please cite this article as: Akhavan Tina, Luhovyy Bohdan L., Panahi Shirin, Kubant Ruslan, Brown Peter H., Anderson G. Harvey, Mechanism Of Action Of Pre-Meal Consumption Of Whey Protein On Glycemic Control In Young Adults, The Journal of Nutritional Biochemistry (2013), doi: 10.1016/j.jnutbio.2013.08.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

T

MECHANISM OF ACTION OF PRE-MEAL CONSUMPTION OF WHEY PROTEIN

MA

NU

SC

RI P

ON GLYCEMIC CONTROL IN YOUNG ADULTS1,2

Tina Akhavana, Bohdan L. Luhovyya, Shirin Panahia, Ruslan Kubanta, Peter H. Brownb, G.

Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto,

CE

a

PT

ED

Harvey Andersona*

b

AC

Ontario, Canada (TA, BLL, SP, RK, GHA) Kraft Foods Global LLC, US (PHB)

*Corresponding author. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, 150 College Street, M5S 3E2, Toronto, ON, Canada. Tel: (416) 978-1832, Fax: (416) 978-5882, E-mail: [email protected] 1

We would like to thank Kraft Foods Global LLC for providing the whey protein and McCain

Foods Ltd. (Toronto, ON) for providing pizza for the experimental meals. This project has been supported by a Collaborative Research and Development Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) and Kraft Canada Inc.

1

ACCEPTED MANUSCRIPT 2

Author disclosure: T Akhavan, B.L. Luhovyy, S Panahi, R Kubant, P.H. Brown, and G.H

Anderson have no conflicts of interest to report. PHB is an employee of Kraft Foods Global LLC

RI P

T

(Chicago, IL).

RUNNING TITLE: Whey protein consumption and glycemia

SC

WORD COUNT: 5354; NUMBER OF FIGURES: 5; NUMBER OF TABLES: 2

NU

ABBREVIATION USED: WP (whey protein), GIP (gastric inhibitory polypeptide), GLP-1 (glucagon-like peptide-1), CCK (cholecystokinin), PYY (peptide tyrosine-tyrosine), CHO

MA

(carbohydrate), BMI (body mass index), VAS (visual analogue scales), ANOVA (analysis of variance), Insulin SECretion (ISEC), DPP-IV (dipeptidyl peptidase IV), BBB (blood-brain

AC

CE

PT

ED

barrier), CNS (central nervous system)

2

ACCEPTED MANUSCRIPT 1 2

ABSTRACT Whey protein (WP), when consumed in small amounts prior to a meal, improves postmeal glycemic control more than can be explained by insulin-dependent mechanisms alone. The

4

objective of the study was to identify the mechanism of action of WP beyond insulin on the

5

reduction of post-meal glycemia. In a randomized crossover study, healthy young men received

6

preloads (300 mL) of WP (10 and 20 g), glucose (10 and 20 g) or water (control). Paracetamol

7

(1.5 g) was added to the preloads to measure gastric emptying. Plasma concentrations of

8

paracetamol, glucose, and ß-cell and gastrointestinal hormones were measured before preloads

9

(baseline) and at intervals before (0-30 min) and after (50-230 min) a preset pizza meal (12

MA

NU

SC

RI P

T

3

kcal/kg). Whey protein slowed pre-meal gastric emptying rate compared to the control and 10 g

11

glucose (P < 0.0001), and induced lower pre-meal insulin and C-peptide than the glucose

12

preloads (P < 0.0001). Glucose, but not WP, increased pre-meal plasma glucose concentrations

13

(P < 0.0001). Both WP and glucose reduced post-meal glycemia (P = 0.0006) and resulted in

14

similar CCK, amylin, ghrelin and GIP responses (P < 0.05). However, compared with glucose,

15

WP resulted in higher post-meal GLP-1 and PYY and lower insulin concentrations, without

16

altering insulin secretion and extraction rates. For the total duration of this study (0-230 min),

17

WP resulted in lower mean plasma glucose, insulin and C-peptide, but higher GLP-1 and PYY

18

concentrations than the glucose preloads. In conclusion, pre-meal consumption of WP lowers

19

post-meal glycemia by both insulin-dependent and insulin-independent mechanisms.

AC

CE

PT

ED

10

20 21 22 23

3

ACCEPTED MANUSCRIPT 24 25

INTRODUCTION When consumed with carbohydrate (CHO), proteins in general [1, 2] and milk proteins specifically [3, 4] reduce glycemic response compared with CHO alone. This effect has been

27

attributed to the is insulinotropic effect of milk proteins [5, 6], and more specifically to whey

28

protein (WP) [7]. The addition of WP [3, 8] or whey peptides [4] to a glucose drink or CHO

29

meal reduces glycemic response, which has been attributed to its rapid digestion [9], and release

30

of amino acids and bioactive peptides during digestion stimulate release of insulin [10], and

31

many gastrointestinal hormones [7].

RI P

SC

NU

Proteins are known to be insulinotrophic but whether WP is more so, as has been

MA

32

T

26

suggested, and it is the only cause of the lowered glycemia after its consumption is unclear. A

34

breakfast and lunch, each containing 28 g of WP and 50 g CHO served to adults with T2D,

35

resulted in higher blood insulin concentrations after both breakfast and lunch and lower glucose

36

after the lunch than when the meals contained lean ham [3]. Additionally, 50 g WP in a meal

37

lowered glycemia more than a similar amount of protein from turkey or egg albumin, and

38

resulted in higher insulin concentrations than the meals with turkey, egg albumin and tuna over

39

240 min [11].

PT

CE

AC

40

ED

33

However, the reduced glycemia after protein consumption either with CHO [2] or alone

41

[9, 12] may be due to increased insulin release but also to release of gut hormones that delay

42

stomach emptying and to the release of incretins that increase efficacy of insulin [7]. Small

43

amounts (as low as 9-10 g) consumed 30 min prior to a meal [13] reduce post-meal

44

concentrations of both glucose and insulin, indicating that insulin cannot be the only cause of the

45

reductions. Only one study has related decreased post-meal glycemia to slower gastric emptying.

4

ACCEPTED MANUSCRIPT 46

Pre-meal consumption of 55 g WP increased glucagon-like peptide-1 (GLP-1) and delayed

47

gastric emptying more than when consumed with a small CHO meal [14]. Therefore, the hypothesis of this study was that WP consumed alone prior to a meal

T

48

improves post-meal glycemic control by both insulin-dependent and -independent mechanisms.

50

The objective was to describe and compare the effect of WP and glucose consumed 30 min

51

before a fixed meal in healthy men on pre- and post-meal and plasma concentrations of glucose,

52

insulin, gastrointestinal hormones regulating stomach emptying and incretins involved in

53

potentiating insulin efficacy and on pre-meal gastric emptying rate.

54

METHODS AND MATERIALS

56

Participants

In a randomized crossover design, 10 men (18-29 y, 18.5-29.4 kg/m2) received preloads

PT

57

ED

55

MA

NU

SC

RI P

49

(300 mL) of WP (10 and 20 g), glucose (10 and 20 g) or water (control). Paracetamol (1.5 g) was

59

added to the preloads to measure gastric emptying. Plasma concentrations of paracetamol,

60

glucose, ß-cell hormones and gastrointestinal hormones were measured before preloads

61

(baseline) as well as at intervals before (0-30 min) and after (50-230 min) a preset pizza meal (12

62

kcal/kg).

63

AC

CE

58

Participants were recruited through advertisements posted on the University of Toronto

64

campus. At initial contact by phone or e-mail, eligibility requirements were described to the

65

potential subjects and they were asked for their age, body weight, height, if they smoke or were

66

taking any medications. Breakfast skippers, smokers, dieters and individuals with diabetes or

67

other metabolic diseases were ineligible to participate in the study. Individuals who fulfilled

68

eligibility requirements were asked to come to the Department for a second screening to

5

ACCEPTED MANUSCRIPT complete questionnaires regarding food habits, food preference and dietary restraint [15] and to

70

read and sign the consent form. Their height and weight were measured to calculate their body

71

mass index (BMI). Qualified subjects were invited to participate in the study. Subjects were

72

financially compensated for completing the study. The procedures of the study were approved by

73

the Human Subject Review Committee, Ethics Review Office at the University of Toronto.

RI P

Based on previous clinical studies on gut hormones with the sample size required for

SC

74

T

69

blood glucose response [4, 16, 17], 10 male subjects, aged 18-29 years with a BMI between

76

18.5-24.9 kg/m2, were recruited and completed the sessions.

NU

75

79

Protocol

Experimental sessions took place at the Department of Nutritional Sciences at University

ED

78

MA

77

of Toronto and subjects participated in the study twice per week. Similar to our previous study

81

[13], a breakfast (300 kcal) of a single serving of a ready-to-eat breakfast cereal (Honey Nut

82

Cheerios; General Mills, Mississauga, Canada), a 250-mL box of 2% milk (Sealtest Skim Milk,

83

Markham, Canada) and a 250-mL box of orange juice (Tropicana Products Inc, Bradenton, FL)

84

was provided to subjects to be consumed at their preferred time in the morning (0600–0900)

85

after a 10-h overnight fast. Subjects were asked not to consume anything between the breakfast

86

and the study session 4 h later (1000 to 1300). Participants were permitted to consume water

87

until 1 h before the session. Each subject arrived at the same chosen time for each session. They

88

were instructed to refrain from alcohol consumption and any unusual exercise and activity the

89

night before the study sessions.

AC

CE

PT

80

90

Upon arrival, subjects filled out the Sleep Habits and Stress Factors Questionnaire and

91

Food Intake and Activity Questionnaire forms. Visual Analogue Scales (VAS) questionnaires

6

ACCEPTED MANUSCRIPT 92

were then completed to measure Physical Comfort and Fatigue/Energy [16, 18]. If they reported

93

significant deviations from their usual patterns, they were rescheduled. Following completion of the VAS questionnaires, an indwelling intravenous catheter was

T

94

inserted in the antecubital vein by a registered nurse and a baseline blood sample obtained.

96

Immediately after, participants drank one of the five preloads within 5 min, followed by

97

completion of a palatability VAS (at 5 min). Blood samples were collected at 10, 20 and 30 min

98

(pre-meal) and 50, 60, 70, 80, 110, 140, 170, 200 and 230 min (post-meal).

NU

SC

RI P

95

99

101

Preloads

MA

100

Pre-meal drinks included iso-volumetric amounts (300 mL) of 10 and 20 g intact WP (NZMP Whey Protein Concentration 392, Fonterra Co- operative Group Limited, New Zealand),

103

and 10 and 20 g glucose control (D-Glucose Monohydrate , Grain Process Enterprises LTD.

104

Scarborough, ON) and a water control. Paracetamol (1.5 g, Panadol, GlaxoSmithKline) was also

105

dissolved in each of the five preloads. Preloads were served chilled with an additional 100 mL

106

of water (in a separate glass) to be consumed upon completion of the drinks to reduce aftertaste.

107

Lemon flavor (0.5 mL, Flavorganics, Newark, NJ), lemon juice (2 tsp, Equality; The Great

108

Atlantic and Pacific Company of Canada Ltd, Toronto, Canada) and sucralose (0.15 g, McNeil

109

Specialty Products Company, New Brunswick, NJ) were added to the drinks to equalize

110

palatability and sweetness and to blind the subjects to the preloads.

AC

CE

PT

ED

102

111 112 113 114

Blood Parameters Blood was collected in 8.5 mL BD™ P800 tubes (BD Diagnostics, Franklin Lakes, NJ) containing spray-dried K2EDTA anticoagulant and proprietary additives to prevent their

7

ACCEPTED MANUSCRIPT immediate proteolytic activity. The tubes were centrifuged at 1300 RCF for 20 min at 4°C.

116

Collected plasma samples were aliquoted in Eppendorf tubes and stored at -70 C for analyses.

117

Plasma concentrations of glucose, paracetamol, insulin, C-peptide, amylin, ghrelin, GLP-1, GIP,

118

CCK and PYY were measured.

RI P

T

115

Plasma glucose was measured using the enzymatic hexokinase method (Roche

119

Diagnostic, Laval, QC, Canada). Insulin and C-peptide were assessed with

121

electrochemiluminescence assays ―ECLIA‖ (Roche Diagnostic, Laval, QC, Canada). These

122

analyses were performed by the Pathology and Laboratory Medicine Division at Mount Sinai

123

Hospital (Toronto, ON, Canada). However, the remaining biomarkers were measured at the

124

Department of Nutritional Sciences, University of Toronto.

MA

NU

SC

120

Free paracetamol was determined with a commercially-available paracetamol

126

(acetaminophen) enzymatic assay (Cambridge Life Sciences, Ely, Cambridge, UK). Human

127

active GLP-1 (# EGLP-35K), total ghrelin (# EZGRT-89K), total GIP (# EZHGIP-54K), total

128

PYY (# EZHPYYT66K) and total amylin (# EZHAT-51K) were measured with ELISA kits

129

(Millipore, Billerica, MA). Human CCK was measured by enzyme immunoassay (# EIA-CCK-1,

130

RayBiotech Inc, Norcross, GA).

AC

CE

PT

ED

125

Plasma concentrations of glucose, insulin and C-peptide were measured at all sampling

131 132

times, however, due to the high cost of the kits and measurements, plasma concentrations of

133

hormones were measured at only baseline, 20 and 30 min (pre-meal) and 60, 80, 140 and 230

134

min (post-meal).

135 136

Meal

8

ACCEPTED MANUSCRIPT Subjects were served a preset pizza meal (12 kcal/ kg body weight of subjects) with a

138

bottled spring water (500 mL Crystal Springs) at 30 min because the primary objective of the

139

study was to determine the mechanisms of pre-meal consumption of WP on post-meal glycemic

140

control. Subjects were given 20 min to consume the pizza meal. Pizza (McCain Foods Ltd.

141

Florenceville, NB) was served at all sessions after cooking from frozen according to

142

manufacturer‘s directions. Detailed information of the nutrient content of the pizza and method

143

of cooking was reported previously [16, 18]. They completed a VAS questionnaire on the

144

palatability of the pizza after finishing the pizza meal. Because there were no differences in

145

palatability or appetite among the preloads, the results are not reported here.

MA

NU

SC

RI P

T

137

148

Data Analysis and Calculation

A two-way repeated measures analysis of variance (ANOVA), using SAS Proc Mixed

PT

147

ED

146

model followed by Tukey‘s post hoc test, was conducted on pre-meal (0-30 min), post-meal (50-

150

230 min) and total (0-230 min) mean plasma concentrations of the dependent measures to test for

151

time and preload effects. Means of the pre-meal, post-meal and total concentrations were used as

152

an estimate of response in treatment measures rather than area under the curve because post-meal

153

concentrations were above baseline and varied in response to preload amount and composition.

154

When an interaction was found, one-way ANOVA was performed to identify the effect of

155

preload at each time of sampling. One-way ANOVA was also used to make summary mean

156

comparisons. Because there were no differences at baseline glucose, hormone and paracetamol

157

concentrations, only the absolute concentrations are reported. Significance was set at P < 0.05.

158

Data were presented as mean ± standard error of the mean (SEM).

AC

CE

149

9

ACCEPTED MANUSCRIPT 159 160

The pre-hepatic insulin secretion (Figure 2) was calculated from deconvolution of plasma concentrations of C-peptide by using the ISEC computer program [19].

RESULTS

163

Participants

Ten subjects completed the study. After completing the study and measurements of the

SC

164

RI P

162

T

161

entire samples, two subjects had higher mean insulin (704 ± 341 vs. 197 ± 5 pmol/L) and C-

166

peptide (2293 ± 797 vs. 1455 ± 26 pmol/L) concentrations compared to other subjects both at

167

baseline and throughout the sessions, most possibly due to either consumption of food before

168

starting the sessions, or physiological differences such as hyperinsulinemia [8]. They were

169

informed and asked to check with their physicians. They were excluded from the analyses,

170

therefore the results are based on eight healthy males with a mean age of 22.9 ± 1.2 y, body

171

weight of 66.4 ± 2.9 kg, height of 1.7 ± 0.0 m, and BMI of 21.8 ± 0.6 kg/m2.

172

Plasma glucose, insulin, C-peptide and amylin

MA

ED

PT

CE

Pre-meal, post-meal and total mean concentrations of plasma glucose, insulin, C-peptide

AC

173

NU

165

174

and amylin, followed by p-values for the preload, time and time by preload interaction effects are

175

shown in Table 1.

176

Pre-meal Mean Plasma Concentrations

177

Over the pre-meal period (0-30 min), mean plasma concentrations of glucose, insulin, C-

178

peptide and amylin were higher (P < 0.0001) after glucose preloads compared with WP and

179

control (Table 1). Both doses of WP increased insulin and C-peptide, however only the 20 g WP

180

increased amylin concentrations above control (P < 0.0001).

10

ACCEPTED MANUSCRIPT 181

Pre-meal concentrations of glucose, insulin, C-peptide (P < 0.0001) and amylin (P = 0.002) were affected by a time by preload interaction (Table 1). One-way ANOVA at each time

183

showed that preloads of glucose, but not WP, increased plasma glucose concentrations in a dose-

184

dependent manner (P < 0.0001) (Figure 1 A). Higher concentrations of insulin and C-peptide

185

after both doses of glucose were observed at 10 min (P < 0.05), 20 min (P < 0.0001) and 30 min

186

(P < 0.0001) (Figure 1 B). Only 20 g WP increased insulin concentrations (P < 0.0001), but C-

187

peptide concentrations were higher after both doses of WP (P < 0.0001) at 20 and 30 min

188

compared to the control, but less than equivalent doses of glucose (Figure 1 C). Amylin

189

concentrations were higher after 20 g WP and both glucose preloads than after 10 g WP or

190

control (Table 1). At 20 min, glucose preloads (P = 0.0008) and at 30 min, glucose preloads and

191

20 g WP (P < 0.0001) increased amylin concentrations compared to control (Figure 1 D).

192

Post-meal Mean Plasma Concentrations

RI P

SC

NU

MA

ED

PT

193

T

182

Over the post-meal period (50-230 min), mean plasma glucose concentrations were lower (P = 0.0006) than control after WP and glucose preloads, which were not different from each

195

other (Table 1). Mean insulin concentrations were lower (P = 0.0003) after 20 g WP than both

196

glucose preloads, and lower after 10 g WP than 20 g glucose. There was no difference between

197

control and WP preloads. Mean C-peptide concentrations were higher (P < 0.0001) after glucose

198

than after WP, and after 20 g glucose than control. Post-meal amylin concentrations were not

199

affected by preload, but were affected similarly by time (P = 0.006) (Table 1).

200

AC

CE

194

Post-meal plasma concentrations of glucose (P < 0.005) and C-peptide (P = 0.03), but not

201

insulin, were affected by a time by preload interaction (Table 1). One-way ANOVA at each time

202

showed that plasma glucose concentrations were lower after both WP doses and 10 g glucose

203

preloads at 60 min (P = 0.003), and after 20 g WP at 70 min (P < 0.05) compared to control

11

ACCEPTED MANUSCRIPT (Figure 1 A). Plasma glucose concentrations at 200 min were lower after 10 g compared to 20 g

205

glucose (P < 0.04). Plasma insulin concentrations, after an initial post-meal rise from 50-70 min

206

decreased to 230 min (Figure 1 B). While there was no difference between WP and control at

207

any of the post-meal times, C-peptide concentrations were higher after 20 g glucose compared

208

with control and WP at 50 min (P < 0.0001), 60 min (P < 0.002) and 70 min (P = 0.0002), with

209

WP at 80 min (P = 0.0009), with control and 20 g WP at 110 min (P = 0.002), and with 10 g

210

glucose and 10 g WP at170 min (P = 0.01) (Figure 1 C). The 10 g glucose preload led to a

211

greater C-peptide concentration compared with control at 50 min (P < 0.0001) and compared

212

with 20 g WP at 70 min (P = 0.0002) (Figure 1 C).

213

Total Mean Plasma Concentrations

MA

NU

SC

RI P

T

204

Over the entire pre- and post-meal period (0-230 min), mean plasma glucose

ED

214

concentrations were lower after WP, but higher after glucose, compared to control (P < 0.0001)

216

(Table 1). Mean plasma concentrations of insulin and C-peptide after WP were lower than after

217

glucose and not different from control (P < 0.0001). Mean plasma amylin concentrations were

218

higher (P = 0.0002) after both glucose and the 20 g WP preloads compared with control (Table

219

1).

221 222

CE

AC

220

PT

215

PLASMA GLP-1, GIP, PYY, CCK AND GHRELIN CONCENTRATIONS Pre-meal, post-meal and total mean concentrations of plasma concentrations of

223

gastrointestinal hormones, followed by p-values for the preload, time and time by preload

224

interaction effects are shown in Table 2.

225

Pre-meal Mean Plasma Concentrations

12

ACCEPTED MANUSCRIPT 226

During the pre-meal period (0-30 min), both doses of WP led to higher mean plasma GLP-1 concentrations than the equivalent dose of glucose or the control (P < 0.0001) (Table 2).

228

Mean plasma GIP concentrations were higher (P = 0.0002) after the treatments than control, but

229

did not differ from each other. Mean plasma PYY concentrations (P = 0.01) were higher than

230

control only after 20 g WP. Pre-meal CCK concentrations were not affected by preloads. Mean

231

plasma concentrations of ghrelin were not different from the preloads compared to control,

232

however, 20 g glucose suppressed (P < 0.05) mean ghrelin concentrations compared with 10 g

233

WP (Table 2).

NU

SC

RI P

T

227

Pre-meal plasma concentrations of GLP-1 (P = 0.01) and GIP were affected by a time by

235

preload interaction (Table 2). Plasma concentrations of GLP-1 were higher after 20 g WP and 20

236

g glucose at 20 min (P = 0.0004), and after 20 g WP at 30 min (P = 0.0001) than control (Figure

237

3 A). Plasma GIP concentrations were higher after all preloads at 20 min (P < 0.0001), and after

238

all preloads except 10 g glucose at 30 min (P = 0.004) than the control (Figure 3 B).

ED

PT

Pre-meal concentrations of PYY and ghrelin were not affected by a time by preload

CE

239

MA

234

interaction. Pre-meal mean CCK concentrations were not affected by time or preload, but there

241

was an interaction (P < 0.04) (Table 2), because the response to the preloads, while not different

242

among them, changed over time.

243

Post-meal Concentrations

244

AC

240

Over the post-meal period (60-230 min), mean plasma concentrations of GLP-1 and PYY

245

were higher (P < 0.0001) after WP than glucose (Table 2). Compared to control, 20 g WP

246

resulted in higher concentrations of PYY (P < 0.0001) and lower GIP (P = 0.03). All preloads

247

raised mean plasma CCK concentrations above control (P < 0.0001). Mean plasma ghrelin

248

concentrations were lower (P < 0.002) only after 20 g glucose compared with 10 g WP (Table 2).

13

ACCEPTED MANUSCRIPT Post-meal plasma concentrations of GLP-1 (P < 0.0001) and PYY (P = 0.0009) were

249

affected only by time, rising to 80 min and then decreasing to 230 min. There was no time by

251

preload interaction effects on these hormones (Table 2).

252

Total Mean Plasma Concentrations

RI P

T

250

Over the entire pre- and post-meal period (0-230 min), mean concentrations of GLP-1

253

and PYY were higher (P < 0.0001) after both doses of WP compared with glucose and control

255

(Table 2). However, mean GIP was not affected by preloads. Mean concentrations of CCK were

256

higher (P < 0.0001) after both glucose and WP than the control. Mean ghrelin concentrations

257

were lower (P = 0.0001) after 20 g glucose than 10 g WP (Table 2).

MA

NU

SC

254

258

GASTRIC EMPTYING RATE (PLASMA PARACETAMOL CONCENTRATIONS)

ED

259

Pre-meal (0-30 min) concentrations of paracetamol were affected by preload (P < 0.0001)

261

and time (P < 0.0001), but there was no time by preload interaction. Mean plasma concentrations

262

of paracetamol were lower after both doses of WP compared to control and 10 g glucose (Figure

263

4).

265 266 267

CE

AC

264

PT

260

Post-meal (50-230 min) concentrations of paracetamol decreased with time (P < 0.0001), but were not affected by preloads. Over the entire pre- and post-meal period (0-230 min), mean plasma paracetamol concentrations were lower after WP compared to 10 g glucose (P < 0.004).

268 269

DISCUSSION

270

The hypothesis that the post-meal plasma glucose concentrations after pre-meal

271

consumption of WP are determined in part by mechanisms beyond insulin is supported by this

14

ACCEPTED MANUSCRIPT study. Both WP and glucose preloads similarly reduce post-meal glycemia. However, their

273

mechanism of action differed. For the total duration of the study, WP resulted in lower mean

274

plasma glucose, insulin and C-peptide, but higher GLP-1 and PYY concentrations than glucose

275

preloads.

RI P

276

T

272

Several lines of evidence show that lower post-meal glycemia after WP, unlike glucose, occurs in part by insulin-independent mechanisms. First, these results are consistent with

278

previous studies indicating that consumption of WP prior to a meal [13] and or fed with CHO

279

[14] improves post-meal glycemia without an increase in post-meal insulin concentrations.

280

However the results are novel not only because they show that relatively small amounts are

281

efficacious when consumed before a meal, but also show that the lower blood insulin

282

concentrations did not occur through alterations in the balance of the kinetics of insulin secretion

283

and extraction. The pre-meal consumption of WP led to lower pre- and post-meal plasma

284

concentrations of glucose, but also of both insulin and C-peptide (Table 1). Because blood

285

insulin concentrations are a product of both secretion and liver extraction C-peptide was

286

measured. C-peptide is secreted in equimolar concentrations with insulin from pancreatic ß cells

287

but unlike insulin is not extracted by the liver. Therefore, the lower plasma concentrations of C-

288

peptide are an indication of lower insulin secretion [20]. When expressed relative to insulin, it is

289

also an indicator of hepatic insulin extraction by the liver. These ratios were similar for WP and

290

glucose, indicating that insulin extractions rates were unchanged (Figure 5) [8][20].

291

Furthermore, the post-meal ratios of C-peptide/insulin were similar after WP and glucose

292

preloads and the control, but glucose concentrations were lowered after both WP and glucose;

293

demonstrating that insulin-independent mechanisms contributed to post-meal regulation of blood

294

glucose concentrations.

AC

CE

PT

ED

MA

NU

SC

277

15

ACCEPTED MANUSCRIPT 295

Second, pre-meal consumption of WP, compared with glucose preloads, led to higher plasma concentrations of GLP-1 and PYY (Table 2). GLP-1 [21] and PYY [22] inhibit gut

297

motility and slow gastric emptying and both rapidly cross the blood-brain barrier (BBB) to

298

directly transmit signals that inhibit gastric emptying. Their increased blood concentration may

299

be explained by both increased synthesis in enteroendocrine L-cells but also by an inhibitory

300

action of WP on dipeptidyl peptidase IV (DPP-IV) which rapidly breaks down circulating

301

peptides[23-25] [7]. Additionally, GLP-1 receptors in the stomach regulate gastric acid secretion

302

and slow motility through ascending vagal afferent signals to the CNS [26, 27]. Taken together,

303

these actions are consistent with the 27% lower pre-meal gastric empting rate after WP compared

304

to glucose and the water control (Figure 4).

RI P

SC

NU

MA

Third, the increase in amylin concentrations after WP, similar to glucose (Table 1), has

ED

305

T

296

not been shown previously, but may be an additional factor in the improved glucose control

307

without additional insulin. Amylin is secreted simultaneously with insulin by the ß-cell with the

308

amylin to glucose ratio of approximately 1:100 [28]. Amylin affects gastric emptying [29-32]

309

and also regulates glucose homeostasis [33, 34] by acting centrally to suppress nutrient-

310

stimulated glucagon secretion from the α-cells [35], which in turn suppresses the release of

311

endogenous hepatic glucose [29-32].

312

AC

CE

PT

306

Fourth, GLP-1 [36, 37] and PYY [38, 39] in the portal vein stimulate hepatic vagal

313

afferents and pancreatic vagal afferents that activate and enhance glucose disposal, thereby,

314

augmenting portal-mediated glucose clearance.

315

The plasma concentrations of ghrelin decreased with time by 30% after the preloads and

316

meal, with the lowest at 140 min (34%). Others have shown that WP suppresses ghrelin release

317

[40]. However, neither WP nor glucose suppressed pre-meal ghrelin concentrations compared

16

ACCEPTED MANUSCRIPT 318

with the control, possibly due to the small total energy content of the WP or glucose preloads

319

(40-80 kcal) [41]. There are some limitations in the study. First, the sample size of eight is relatively small,

T

320

but was based on previous studies of sample sizes required to detect treatment effects on short-

322

term physiological responses in healthy individuals [13]. However, it is unlikely this affected the

323

conclusion. Based on a calculation of sample size using the variability found in this study, post-

324

meal PYY concentrations after 10 g WP and control would require a sample size of 32 subjects

325

to identify a difference, if it existed. Secondly, the paracetamol absorption test is an indirect

326

method used to measure of liquid gastric emptying rate in humans [12, 42, 43] and provides a

327

reliable, reasonably accurate and inexpensive estimate [44], but it does not have the precision of

328

scintigraphy, which is technically challenging and requires expensive equipment and special

329

licensing for use of radioactive substances [45]. However, while the quantitative rates of

330

stomach emptying may not be as accurate, the primary purpose of the measure was to compare

331

the response to treatments, and differences were found. Third, total ghrelin accounting for both

332

active (acyl ghrelin) and inactive forms of ghrelin (des-acyl ghrelin) was measured in this study.

333

Active ghrelin is now recognized as the preferred measure as it relates more clearly to

334

functionality [46]. Fourth, because this study assessed the acute and short-term effect of WP on

335

glycemia and hormonal responses in healthy young men, the effectiveness of WP consumption

336

on long-term glycemic control is unclear. However, the results of this study adds to the

337

accumulative evidence that whey protein has potential in the dietary management of obesity and

338

T2D [7] and provides encouragement for both short and longer term studies in such individuals.

339 340

AC

CE

PT

ED

MA

NU

SC

RI P

321

In conclusion, WP consumption prior to a meal results in post-meal glucose control by both insulin-dependent and –independent mechanisms.

17

ACCEPTED MANUSCRIPT 341

344 345

We thank Drs. Paul Pencharz, Thomas Wolever, and Ravi Retnakaran for their

T

343

ACKNOWLEDGMENTS

intellectual contribution and constructive guidance during the research.

RI P

342

The authors’ responsibilities were as follows—TA, PHB and GHA: conceived and designed the study; GHA: applied for and received the grant from NSERC; TA and BLL:

347

prepared the ethics application, recruited the volunteers, conducted the clinical session TA, RK,

348

SP and BLL: performed the biochemical analyses; TA: obtained and collated the data and

349

performed the statistical analyses; all authors contributed to the writing of this manuscript.

AC

CE

PT

ED

MA

NU

SC

346

18

ACCEPTED MANUSCRIPT REFERENCES 350

1.

Gannon MC, Nuttall FQ, Neil BJ, Westphal SA. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism 1988;

352

37(11):1081-1088. 2.

RI P

353

T

351

Karamanlis A, Chaikomin R, Doran S, Bellon M, Bartholomeusz FD, Wishart JM, Jones KL, Horowitz M, Rayner CK. Effects of protein on glycemic and incretin responses and

355

gastric emptying after oral glucose in healthy subjects. Am J Clin Nutr 2007; 86(5):1364-

356

1368.

NU

3.

Frid AH, Nilsson M, Holst JJ, Bjorck IM. Effect of whey on blood glucose and insulin

MA

357

SC

354

responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin

359

Nutr 2005; 82(1):69-75.

supplement decreases post-prandial glycemia. Nutr J 2009; 8:47.

361 362

Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V. A whey protein

PT

4.

5.

Akhavan T, Panahi S, Anderson GH, Luhovyy BL. Application of dairy-derived

CE

360

ED

358

ingredients in food intake and metabolic regulation. In: Dairy-derived ingredients: Food

364

and nutraceutical uses. Edited by Corredig M. Cambridge, UK: Woodhead Publishing

365

Ltd; 2009; 212-237.

366

AC

363

6.

and satiety. J Am Coll Nutr 2007; 26(6):704S-712S.

367 368

7.

371

Jakubowicz D, Froy O. Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes. J Nutr Biochem 2013; 24(1):1-5.

369 370

Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake

8.

Lan-Pidhainy X, Wolever TM. The hypoglycemic effect of fat and protein is not attenuated by insulin resistance. Am J Clin Nutr 2010; 91(1):98-105.

19

ACCEPTED MANUSCRIPT 372

9.

Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrere B. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci

374

U S A 1997; 94(26):14930-14935. 10.

Nilsson M, Holst JJ, Bjorck IM. Metabolic effects of amino acid mixtures and whey

RI P

375

T

373

protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr

377

2007; 85(4):996-1004.

energy intake in lean men. Br J Nutr 2010; 104(8):1241-8.

379 380

Pal S, Ellis V. The acute effects of four protein meals on insulin, glucose, appetite and

NU

11.

12.

Hall WL, Millward DJ, Long SJ, Morgan LM. Casein and whey exert different effects on

MA

378

SC

376

plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr

382

2003; 89(2):239-248. 13.

Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH. The Effect of Pre-meal

PT

383

ED

381

Consumption of Whey Protein and its Hydrolysate on Food Intake and Post-Meal

385

Glycemia and Insulin Responses in Young Adults. Am J Clin Nutr 2010; 91(4):966-975. 14.

Ma J, E. SJ, Cukier K, Maddox AF, Wishart JM, Clifton PM, Horowitz M, Rayner CK.

AC

386

CE

384

387

Effects of a protein ‗preload‘ on gastric emptying, glycemia, and gut hormones after a

388

carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009; 32(9):1600-

389

1602.

390

15.

WB Saunders and Co 1980:208-217.

391 392

Herman CP, Polivy J. Restrained eating. In: AJ Stunkard Ed. Obesity Philadelphia, PA:

16.

Akhavan T, Anderson GH. Effects of glucose-to-fructose ratios in solutions on subjective

393

satiety, food intake, and satiety hormones in young men. Am J Clin Nutr 2007;

394

86(5):1354-1363.

20

ACCEPTED MANUSCRIPT 395

17.

different amounts of intact and hydrolysed proteins. Br J Nutr 2008; 100(1):61-69.

396

18.

Hamedani A, Akhavan T, Samra RA, Anderson GH. Reduced energy intake at breakfast

T

397

Claessens M, Saris WH, van Baak MA. Glucagon and insulin responses after ingestion of

is not compensated for at lunch if a high-insoluble-fiber cereal replaces a low-fiber

399

cereal. Am J Clin Nutr 2009; 89(5):1343-1349.

20.

Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes & Metabolism 1984; 33:486-494.

403 404

NU

Comput Methods Programs Biomed 1996; 50(3):253-264.

401 402

Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion.

SC

19.

21.

MA

400

RI P

398

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic

406

effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1):E981-988. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30(4):255-262.

408

23.

Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper

AC

409

PT

22.

CE

407

ED

405

410

S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo

411

by dipeptidyl peptidase IV. Nat Biotechnol 1997(15):673-677.

412

24.

characterization of human PYY(3-36) and PYY(1-36). Peptides 1989; 10(4):797-803.

413 414

Eberlein GA, Eysselein VE, Schaeffer M, al. e. A new molecular form of PYY: structural

25.

Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahren B.

415

Glucose-induced incretin hormone release and inactivation are differently modulated by

416

oral fat and protein in mice. Endocrinology 2006; 147(7):3173-3180.

21

ACCEPTED MANUSCRIPT 417

26.

Schmidtler J, Dehne K, Allescher H-D, Schusdziarra V, Classen M, Holst JJ, Polack A, Schepp W. Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-

419

linking, and radioligand binding. Am J Physiol 1994; 267 (3 Pt 1):G423-G432. 27.

Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like

RI P

420

T

418

peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1

422

receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose

423

homeostasis. Diabetes & Metabolism 2004; 53(9):2492-2500. 28.

NU

424

SC

421

Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic

426

humans. Diabetes 1990; 39(6):752-756. 29.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C,

ED

427

MA

425

Kolterman OG. A randomized study and open-label extension evaluating the long-term

429

efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care

430

2002; 25(4):724-730.

CE

30.

Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J. Islet amyloid

AC

431

PT

428

432

polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat

433

pancreatic islets. Am J Physiol 1999; 276(1 Pt 1):E19-24.

434

31.

Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR. Influence of

435

islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin

436

release from perifused rat islets. Diabetes 1993; 42(2):330-335.

437

32.

Degano P, Silvestre RA, Salas M, Peiro E, Marco J. Amylin inhibits glucose-induced

438

insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul

439

Pept 1993; 43(1-2):91-96.

22

ACCEPTED MANUSCRIPT 440

33.

Karhunen LJ, Juvonen KR, Huotari A, Purhonen AK, Herzig KH. Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul Pept 2008;

442

149(1-3):70-78. 34.

Reidelberger RD, Arnelo U, Granqvist L, Permert J. Comparative effects of amylin and

RI P

443

T

441

cholecystokinin on food intake and gastric emptying in rats. Am J Physiol Regul Integr

445

Comp Physiol 2001; 280(3):R605-611.

rats. Metabolism: Clinical and Experimental 1997; 46 (1):67-70.

447 448

Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in

NU

35.

36.

Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal

MA

446

SC

444

hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol

450

1996; 271(5 Pt 1):E808-E813.

ED

449

37.

Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006; 3(3):153-165.

452

38.

van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl

PT

451

H. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.

454

Diabetes & Metabolism 2004; 53(8):1949-1952. 39.

AC

455

CE

453

Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces

456

food intake and body weight and improves insulin sensitivity in rodent models of diet-

457

induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291(2):R367-375.

458

40.

Bowen J, Noakes M, Clifton PM. Appetite hormones and energy intake in obese men

459

after consumption of fructose, glucose and whey protein beverages. Int J Obes (Lond)

460

2007; 31(11):1696-1703.

23

ACCEPTED MANUSCRIPT 461

41.

Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not

463

predict intermeal interval in humans. J Clin Endocrinol Metab 2004; 89(3):1319-1324. 42.

Sanaka M, Kuyama Y, Yamanaka M. Guide for judicious use of the paracetamol

RI P

464

T

462

absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 1998;

466

33(6):785-791. 43.

Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a

NU

467

SC

465

marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001;

469

46(10):2256-2262.

470

44.

MA

468

Naslund E, Bogefors J, Gryback P, Jacobsson H, Hellstrom PM. Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer

472

assessment techniques. Scand J Gastroenterol 2000; 35(4):375-379. Deane AM, Fraser RJ, Chapman MJ. Prokinetic drugs for feed intolerance in critical

46.

CE

illness: current and potential therapies. Crit Care Resusc 2009; 11(2):132-143.

474 475

PT

45.

Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga

AC

473

ED

471

476

M. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;

477

54(1):18-24.

478

24

ACCEPTED MANUSCRIPT Table 1 Mean plasma concentrations of glucose, insulin, C-peptide, and amylin after the

Control

10 g Glucose

20 g Glucose

(mmol/L)

meal2 Post-

Preload

Time

Interaction

5.3 ± 0.1c

<0.0001

<0.0001

<0.0001

5.7 ± 0.1b

5.6 ± 0.1b

0.0006

<0.0001

<0.005

5.5 ± 0.1c

5.5 ± 0.1c

<0.0001

<0.0001

<0.0001

82.8 ± 9.1c

106.0 ± 13.6c

<0.0001

<0.0001

<0.0001

266.6 ± 13.4a

218.1 ± 11.3bc

208.5 ± 9.4c

0.0003

<0.0001

NS

5.0 ± 0.1c

6.5 ± 0.2b

6.8 ± 0.3a

6.0 ± 0.1a

5.7 ± 0.1b

6.0 ± 0.1b

5.7 ± 0.1b

6.0 ± 0.1a

6.0 ± 0.1a

36.4 ± 3.8d

153.1 ± 16.3b

207.9 ± 24.3a

229.8 ± 11.5bc

240.5 ± 11.8ab

170.3 ± 11.9c

213.6 ± 10.4b

248.6 ± 12.1a

176.5 ± 10.3c

177.0 ± 9.0c

<0.0001

<0.0001

<0.0001

530.7 ± 24.2d

1081.8 ± 73.8b

1280.3 ± 112.3a

772.4 ± 50.1c

847.8 ± 48.9c

<0.0001

<0.0001

<0.0001

1604.7 ± 47.7bc

1725.8 ± 45.7b

2024.9 ± 63.4a

1589.8 ± 44.4c

1558.2 ± 40.7c

<0.0001

<0.0001

0.03

1274.2 ± 59.4c

1527.6 ± 48.6b

1795.8 ± 65.0a

1338.3 ± 50.6c

1339.6 ± 45.3c

<0.0001

<0.0001

<0.0001

18.5 ± 2.6b

27.3 ± 3.5a

28.7 ± 3.6a

21.3 ± 2.2b

26.7 ± 3.5a

<0.0001

0.0004

0.002

35.7 ± 2.8

38.2 ± 3.1

39.5 ± 3.5

36.4 ± 2.6

35.8 ± 3.3

NS

0.006

NS

28.3 ± 2.3c

33.5 ± 2.4a

34.9 ± 2.6a

29.9 ± 2.0bc

31.9 ± 2.5ab

0.0002

<0.0001

<0.005

3

Pre-

(pmol/L)

meal Post-

ED

Insulin

(pmol/L)

meal Postmeal Total Pre-

CE

Pre-

AC

C-peptide

PT

meal Total

5.1 ± 0.1c

MA

meal

Total4

P (Two-way ANOVA)

SC

Pre-

(pM)

20 g WP

NU

Glucose

Amylin

10 g WP

RI P

Biomarkers

T

preloads1

meal Postmeal Total

1

All values are ± SEM. n = 8. Data were analyzed for pre-meal, post-meal and total for preload ,

time, and preload x time interaction by 2-factor ANOVA (Proc Mixed) and significance was assessed using Tukey's post hoc, P < 0.05 for all, NS (not significant) 25

ACCEPTED MANUSCRIPT 2

Pre-meal values are means of all plasma concentrations before the test meal and calculated from

0-30 min Post-meal values are means of all plasma concentrations after the test meal and calculated from

T

3

4

RI P

50-230 min for plasma glucose, insulin and C-peptide and from 60-230 for plasma amylin Total values are means of all plasma concentrations before and after the test meal and

AC

CE

PT

ED

MA

NU

SC

calculated from 0-230 min

26

ACCEPTED MANUSCRIPT Table 2 Mean plasma concentrations of gastrointestinal hormones after the preloads1

10 g WP

20 g WP

Preload

Time

Interaction

4.9 ± 0.4c

5.3 ± 0.4c

5.8 ± 0.4bc

5.9 ± 0.3b

7.2 ± 0.4a

<0.0001

0.01

6.4 ± 0.4b

5.9 ± 0.3b

6.3 ± 0.4b

8.0 ± 0.4a

RI P

<0.0001

8.5 ± 0.5a

<0.0001

5.8 ± 0.3c

5.6 ± 0.2c

6.1 ± 0.3c

7.1 ± 0.3b

7.9 ± 0.3a

<0.0001

<0.0001

NS

82.7 ± 9.7b

157.6 ± 14.5a

139.3 ± 14.8a

152.9 ± 15.1a

166.5 ± 13.5a

0.0002

0.002

<0.04

393.9 ± 21.1a

372.5 ± 17.7ab

367.4 ± 20.3ab

364.5 ± 16.1ab

319.6 ± 18.6b

0.03

<0.0001

NS

260.5 ± 24.3

280.4 ± 18.6

269.6 ± 20.1

273.8 ± 18.0

254.0 ± 15.8

NS

<0.0001

0.0021

199.6 ± 11.2b

202.1 ± 8.1ab

204.9 ± 9.0ab

223.0 ± 7.8ab

230.3 ± 11.3a

0.01

NS

NS

231.0 ± 10.3bc

223.2 ± 6.5c

220.4 ± 6.5c

249.6 ± 8.6ab

270.4 ± 12.7a

<0.0001

0.0009

NS

217.6 ± 7.8b

214.2 ± 5.2b

213.8 ± 5.4b

238.2 ± 6.2a

253.2 ± 9.1a

<0.0001

<0.0001

NS

100.2 ± 8.8

103.5 ± 9.1

101.5 ± 7.8

122.0 ± 10.0

114.0 ± 8.1

NS

NS

<0.04

77.8 ± 8.1b

127.5 ± 8.3a

113.8 ± 6.4a

123.5 ± 9.0a

123.0 ± 8.1a

<0.0001

NS

NS

87.4 ± 6.1b

117.2 ± 6.3a

108.6 ± 5.0a

122.9 ± 6.4a

119.1 ± 5.7a

<0.0001

NS

0.04

405.0 ± 42.2ab

444.0 ± 64.6ab

322.7 ± 27.0b

512.3 ± 95.7a

407.4 ± 61.8ab

<0.05

NS

NS

304.1 ± 30.3ab

340.5 ± 32.0ab

215.6 ± 21.6b

431.7 ± 78.1a

328.0 ± 35.1ab

<0.002

NS

NS

347.4 ± 26.0bc

384.8 ± 33.6ab

261.5 ± 18.2c

466.2 ± 60.3a

362.0 ± 33.3abc

0.0001

0.0006

NS

2

meal

Post3

Total4 GIP

Pre-

(pg/mL)

meal Post-

Total PYY

Pre-

(pg/ mL)

meal Post-

Total CCK

Pre-

(ng/mL)

meal Postmeal Total

Ghrelin

Pre-

(pg/mL)

meal

CE

meal

ED

meal

NU

meal

T

20 g Glucose

SC

(pg/mL)

Pre-

10 g Glucose

MA

GLP-1

Control

PT

Biomarkers

AC

P (Two-way ANOVA)

<0.0001

NS

Postmeal Total

27

ACCEPTED MANUSCRIPT 1

All values are ± SEM. n = 8. Data were analyzed for pre-meal, post-meal and total for preload ,

time, and preload x time interaction by 2-factor ANOVA (Proc Mixed) and significance was

Pre-meal values are means of all plasma concentrations before the test meal and calculated from

RI P

2

T

assessed using Tukey's post hoc, P < 0.05 for all, NS (not significant)

0-30 min

Post-meal values are means of all plasma concentrations after the test meal and calculated from

SC

3

4

NU

60-230 min

Total values are means of all plasma concentrations before and after the test meal and

AC

CE

PT

ED

MA

calculated from 0-230 min

28

ACCEPTED MANUSCRIPT FIGURE LEGENDS

480

FIGURE 1 Mean (± SEM) pre- and post-meal plasma concentrations of glucose (A), insulin (B),

481

C-peptide (C) and amylin (D) in 8 healthy men after intake of water (····Ӂ····), 10 g glucose

482

(····Δ····), 20 g glucose (····▲····), 10 g whey protein (—○—), and 20 g whey protein (—●—).

483

Different superscripts at each measured time are different between preloads (one-way ANOVA,

484

Proc Mixed, followed by Tukey‘s post hoc, P < 0.05).

SC

RI P

T

479

NU

485

FIGURE 2 Mean (± SEM) pre-meal, post-meal and total insulin secretion rate (pmol/kg/min)

487

calculated from plasma C-peptide concentrations (pmol/L) after the whey protein and glucose

488

preload consumption (n = 8). Two-factor repeated-measures ANOVA followed by Tukey‘s post

489

hoc was used to compare the effect of preloads (means with different superscripts at pre-meal (0-

490

30 min), post-meal (50-230 min) and total (0-230 min) are different, P < 0.0001).

PT

ED

MA

486

491

FIGURE 3 Mean (± SEM) pre-and post-meal plasma concentrations of GLP-1 (A) and GIP (B)

493

in 8 healthy men after intake of water (····Ӂ····), 10 g glucose (····Δ····), 20 g glucose (····▲····), 10

494

g whey protein (—○—), and 20 g whey protein (—●—). Different superscripts at each measured

495

time are different between preloads (one-way ANOVA, Proc Mixed, followed by Tukey‘s post

496

hoc, P < 0.05).

AC

CE

492

497 498

FIGURE 4 Mean (± SEM) pre-meal plasma concentrations of paracetamol after the whey

499

protein and glucose preload consumption (n = 8). Two-factor repeated-measures ANOVA

500

followed by Tukey‘s post hoc was used to compare the effect of preloads (means with different

29

ACCEPTED MANUSCRIPT 501

superscripts at pre-meal (0-30 min) are different, P < 0.0001) and time (P < 0.0001), but no

502

interaction effect.

T

503

FIGURE 5 Mean (± SEM) ratio of pre-meal and post-meal plasma concentrations of C-

505

peptide/insulin after the whey protein and glucose preload consumption (n = 8). Two-factor

506

repeated-measures ANOVA followed by Tukey‘s post hoc was used to compare the effect of

507

preloads (means with different superscripts at pre-meal (0-30 min) and post-meal (50-230 min)

508

are different, P < 0.05).

AC

CE

PT

ED

MA

NU

SC

RI P

504

509

30

510

AC

CE

PT

ED

MA

NU

SC

RI P

T

ACCEPTED MANUSCRIPT

31

MA

NU

SC

RI P

T

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

511

32

ED

MA

NU

SC

RI P

T

ACCEPTED MANUSCRIPT

AC

CE

PT

512

33

MA

NU

SC

RI P

T

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

513

34

SC

RI P

T

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

514

35